Amgen stock: Barclays lifts price target to 430 US dollars
Published on 11/17/2026 at 15:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBarclays changes its view
- Emily Field raised Barclays' price target after Amgen's third-quarter report.
- The analyst kept an Equal Weight rating on the shares.
- Barclays cited strong performance from most growth drivers alongside disappointing pelacarsen data.
Barclays analyst Emily Field raised the firm's price target for Amgen to 430 US dollars from 400 US dollars on Monday, November 16, while retaining an Equal Weight rating, according to a Markets Insider report. The analyst's note followed Amgen's third-quarter results.
What Barclays highlighted
Field pointed to strong performance from most of Amgen's growth drivers. The note also referenced disappointing pelacarsen data, leaving the Equal Weight rating unchanged even as the target moved higher.
The analyst action gives investors a fresh view of how Amgen's pipeline and established products are being weighed after the latest quarterly update. The target increase is an analyst assessment, not a change to Amgen's own financial outlook.
Amgen stock trades in euros
Amgen stock traded at 420.03 euros on Lang & Schwarz at 15:41 CET on Tuesday, November 17.
Amgen company facts
- Company: Amgen Inc.
- ISIN: US0311621009
- Ticker: AMGN
- Quoted price: 420.03 euros
- Trading venue: Lang & Schwarz
- Quote time: 15:41 CET, Tuesday, November 17, 2026
Healthcare and biotechnology shares remain part of the broader market setting covered in Current market reports.
More news and analyses on Amgen stock.
